Thera-SAbDab

SACITUZUMAB

> Structural Summary

Therapeutic	Sacituzumab
Target	TACSTD2
Heavy Chain	QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS
Light Chain	DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb ADC
Isotype	G1
Highest Clinical Trial (June '19)	Preregistration
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2016
INN Year Recommended	2017
Companies Involved	IBC Pharmaceuticals, Immunomedics, University of Wisconsin Comprehensive Cancer Center, Yale University
Conditions Approved	na
Conditions Active	Breast cancer, Prostate cancer, Solid tumours, Urogenital cancer, Endometrial cancer
Conditions Discontinued	Pancreatic cancer, Small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]